163 related articles for article (PubMed ID: 28993697)
1. N-terminal gelsolin fragment potentiates TRAIL mediated death in resistant hepatoma cells.
Meyer K; Kwon YC; Ray RB; Ray R
Sci Rep; 2017 Oct; 7(1):12803. PubMed ID: 28993697
[TBL] [Abstract][Full Text] [Related]
2. Notch1 signaling sensitizes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression.
Wang C; Qi R; Li N; Wang Z; An H; Zhang Q; Yu Y; Cao X
J Biol Chem; 2009 Jun; 284(24):16183-16190. PubMed ID: 19376776
[TBL] [Abstract][Full Text] [Related]
3. Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation.
Carlisi D; D'Anneo A; Angileri L; Lauricella M; Emanuele S; Santulli A; Vento R; Tesoriere G
J Cell Physiol; 2011 Jun; 226(6):1632-41. PubMed ID: 21413021
[TBL] [Abstract][Full Text] [Related]
4. MK-2206 induces cell cycle arrest and apoptosis in HepG2 cells and sensitizes TRAIL-mediated cell death.
Jiao P; Zhou YS; Yang JX; Zhao YL; Liu QQ; Yuan C; Wang FZ
Mol Cell Biochem; 2013 Oct; 382(1-2):217-24. PubMed ID: 23797319
[TBL] [Abstract][Full Text] [Related]
5. Nutlin-3 Promotes TRAIL-Induced Liver Cancer Cells Apoptosis by Activating p53 to Inhibit bcl-2 and Surviving Expression.
Zhang C; Ni J; Fan W; Hou J
Ann Clin Lab Sci; 2022 Jul; 52(4):601-610. PubMed ID: 36197780
[TBL] [Abstract][Full Text] [Related]
6. Butein sensitizes human hepatoma cells to TRAIL-induced apoptosis via extracellular signal-regulated kinase/Sp1-dependent DR5 upregulation and NF-kappaB inactivation.
Moon DO; Kim MO; Choi YH; Kim GY
Mol Cancer Ther; 2010 Jun; 9(6):1583-95. PubMed ID: 20515942
[TBL] [Abstract][Full Text] [Related]
7. Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression.
Ding J; Polier G; Köhler R; Giaisi M; Krammer PH; Li-Weber M
J Biol Chem; 2012 Jan; 287(1):641-649. PubMed ID: 22086925
[TBL] [Abstract][Full Text] [Related]
8. Simultaneously targeting Bcl-2 and Akt pathways reverses resistance of nasopharyngeal carcinoma to TRAIL synergistically.
Li SS; Tang QL; Wang SH; Chen YH; Liu JJ; Yang XM
Tumori; 2011; 97(6):762-70. PubMed ID: 22322844
[TBL] [Abstract][Full Text] [Related]
9. Galectin-1 Modulates the Survival and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Sensitivity in Human Hepatocellular Carcinoma Cells.
Li J; Sun RR; Yu ZJ; Liang H; Shen S; Kan Q
Cancer Biother Radiopharm; 2015 Oct; 30(8):336-41. PubMed ID: 26348206
[TBL] [Abstract][Full Text] [Related]
10. N-terminal region of gelsolin induces apoptosis of activated hepatic stellate cells by a caspase-dependent mechanism.
Mazumdar B; Meyer K; Ray R
PLoS One; 2012; 7(8):e44461. PubMed ID: 22952982
[TBL] [Abstract][Full Text] [Related]
11. Purified vitexin compound 1 induces apoptosis through activation of FOXO3a in hepatocellular carcinoma.
Wang JG; Zheng XX; Zeng GY; Zhou YJ; Yuan H
Oncol Rep; 2014 Jan; 31(1):488-96. PubMed ID: 24247909
[TBL] [Abstract][Full Text] [Related]
12. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
13. TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.
Koehler BC; Urbanik T; Vick B; Boger RJ; Heeger S; Galle PR; Schuchmann M; Schulze-Bergkamen H
World J Gastroenterol; 2009 Dec; 15(47):5924-35. PubMed ID: 20014456
[TBL] [Abstract][Full Text] [Related]
14. Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-dependent mechanisms.
Yang L; Wang Y; Zheng H; Zhang D; Wu X; Sun G; Yang T
J Chemother; 2017 Jun; 29(3):179-188. PubMed ID: 28067150
[TBL] [Abstract][Full Text] [Related]
15. Msi1 confers resistance to TRAIL by activating ERK in liver cancer cells.
Liu N; Chen T; Wang X; Yang D; Xue B; Zhu H
FEBS Lett; 2015 Apr; 589(8):897-903. PubMed ID: 25747387
[TBL] [Abstract][Full Text] [Related]
16. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
[TBL] [Abstract][Full Text] [Related]
17. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
Wang W; Gallant JN; Katz SI; Dolloff NG; Smith CD; Abdulghani J; Allen JE; Dicker DT; Hong B; Navaraj A; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(3):229-38. PubMed ID: 21725212
[TBL] [Abstract][Full Text] [Related]
18. Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner.
Chen M; Wang X; Zha D; Cai F; Zhang W; He Y; Huang Q; Zhuang H; Hua ZC
Sci Rep; 2016 Oct; 6():35468. PubMed ID: 27752089
[TBL] [Abstract][Full Text] [Related]
19. Gli2 silencing enhances TRAIL-induced apoptosis and reduces tumor growth in human hepatoma cells in vivo.
Zhang DW; Li HY; Lau WY; Cao LQ; Li Y; Jiang XF; Yang XW; Xue P
Cancer Biol Ther; 2014; 15(12):1667-76. PubMed ID: 25535898
[TBL] [Abstract][Full Text] [Related]
20. Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms.
Charette N; De Saeger C; Horsmans Y; Leclercq I; Stärkel P
Cell Death Dis; 2013 Jan; 4(1):e471. PubMed ID: 23348585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
